MusclePharm terminates CFO Gary Shirshac; names Anthony Todaro interim CFO

MusclePharm Corp

Gary Shirshac terminated as CFO effective July 10, 2023.
Anthony Todaro appointed as interim CFO as of same date.
Company remains in Chapter 11 bankruptcy (filed Dec. 15, 2022, case 22-14422).
Monthly operating reports from the bankruptcy case attached as exhibits.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gary Shirshac

Chief Financial Officer

MusclePharm Corp

Effective: 2023-07-10
Successor: Anthony Todaro
Filed: July 19, 2023, 7:59 PM ET

Effective as of July 10, 2023, MusclePharm Corporation (the “Company”) terminated Chief Financial Officer, Gary Shirshac.

Appointed (interim)

Anthony Todaro

interim Chief Financial Officer

MusclePharm Corp

Effective: 2023-07-19
Filed: July 19, 2023, 7:59 PM ET

As of this filing, Anthony Todaro has been named as the Company’s interim Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Shirshac was terminated as Chief Financial Officer at MusclePharm Corp.

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

Effective as of July 10, 2023, MusclePharm Corporation (the “Company”) terminated Chief Financial Officer, Gary Shirshac.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Anthony Todaro was appointed as interim Chief Financial Officer at MusclePharm Corp.

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

As of this filing, Anthony Todaro has been named as the Company’s interim Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-23-024915

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.